USD 9.4
(0.11%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 194.33 Million USD | -3.24% |
2022 | 200.84 Million USD | 6.92% |
2021 | 187.84 Million USD | 3.2% |
2020 | 182.02 Million USD | 63.89% |
2019 | 111.06 Million USD | 12.9% |
2018 | 98.37 Million USD | 13.55% |
2017 | 86.64 Million USD | 90.88% |
2016 | 45.38 Million USD | 5.17% |
2015 | 43.15 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 174.72 Million USD | -4.48% |
2024 Q1 | 182.92 Million USD | -5.87% |
2023 Q4 | 194.33 Million USD | 8.55% |
2023 Q3 | 179.02 Million USD | 1.87% |
2023 Q1 | 188.71 Million USD | -6.04% |
2023 Q2 | 175.72 Million USD | -6.88% |
2023 FY | 194.33 Million USD | -3.24% |
2022 Q3 | 178.68 Million USD | -2.68% |
2022 FY | 200.84 Million USD | 6.92% |
2022 Q1 | 178.67 Million USD | -4.88% |
2022 Q2 | 183.61 Million USD | 2.77% |
2022 Q4 | 200.84 Million USD | 12.4% |
2021 Q3 | 183.38 Million USD | 3.85% |
2021 Q4 | 187.84 Million USD | 2.43% |
2021 FY | 187.84 Million USD | 3.2% |
2021 Q1 | 174.61 Million USD | -4.07% |
2021 Q2 | 176.58 Million USD | 1.13% |
2020 FY | 182.02 Million USD | 63.89% |
2020 Q1 | 139.03 Million USD | 25.18% |
2020 Q4 | 182.02 Million USD | 18.71% |
2020 Q3 | 153.34 Million USD | 9.19% |
2020 Q2 | 140.43 Million USD | 1.01% |
2019 FY | 111.06 Million USD | 12.9% |
2019 Q1 | 100.63 Million USD | 2.3% |
2019 Q2 | 98.1 Million USD | -2.52% |
2019 Q3 | 104.85 Million USD | 6.89% |
2019 Q4 | 111.06 Million USD | 5.92% |
2018 Q4 | 98.37 Million USD | 3.67% |
2018 FY | 98.37 Million USD | 13.55% |
2018 Q1 | 94.45 Million USD | 9.02% |
2018 Q2 | 95.61 Million USD | 1.24% |
2018 Q3 | 94.89 Million USD | -0.76% |
2017 Q2 | 6.22 Million USD | 100.42% |
2017 Q1 | 3.1 Million USD | -93.16% |
2017 FY | 86.64 Million USD | 90.88% |
2017 Q4 | 86.64 Million USD | 26.36% |
2017 Q3 | 68.56 Million USD | 1001.49% |
2016 FY | 45.38 Million USD | 5.17% |
2016 Q4 | 45.38 Million USD | 0.0% |
2015 FY | 43.15 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Esperion Therapeutics, Inc. | 660.79 Million USD | 70.591% |
Theratechnologies Inc. | 98.63 Million USD | -97.016% |
Safety Shot Inc | 3.89 Million USD | -4893.135% |
Cosmos Health Inc. | 30.25 Million USD | -542.376% |
Cronos Group Inc. | 43.73 Million USD | -344.336% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 76.224% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -301.146% |
Organogenesis Holdings Inc. | 181.36 Million USD | -7.153% |
Universe Pharmaceuticals INC | 13.75 Million USD | -1312.9% |
ProPhase Labs, Inc. | 42.54 Million USD | -356.786% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -2119.45% |
Dynavax Technologies Corporation | 375.02 Million USD | 48.181% |
Radius Health, Inc. | 804.29 Million USD | 75.838% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -2013.115% |
Alvotech | 1.88 Billion USD | 89.677% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -3065.271% |
Alpha Teknova, Inc. | 38.55 Million USD | -404.098% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -41.984% |
SCYNEXIS, Inc. | 55.45 Million USD | -250.469% |
Harrow Health, Inc. | 241.75 Million USD | 19.614% |
Biofrontera Inc. | 23.13 Million USD | -739.859% |
DURECT Corporation | 30.4 Million USD | -539.134% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 60.133% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 58.799% |
RedHill Biopharma Ltd. | 20.97 Million USD | -826.37% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -18.566% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -270.048% |
SIGA Technologies, Inc. | 57.97 Million USD | -235.192% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 11.586% |
Shineco, Inc. | 47.6 Million USD | -308.252% |
Phibro Animal Health Corporation | 725.54 Million USD | 73.215% |
Procaps Group S.A. | 462.06 Million USD | 57.942% |
TherapeuticsMD, Inc. | 14.02 Million USD | -1285.929% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -88430.468% |
Viatris Inc. | 27.21 Billion USD | 99.286% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -3065.271% |
Rockwell Medical, Inc. | 30.88 Million USD | -529.282% |
Incannex Healthcare Limited | 5.83 Million USD | -3233.362% |
Aytu BioPharma, Inc. | 90.37 Million USD | -115.022% |
Tilray Brands, Inc. | 892.11 Million USD | 78.216% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 79.498% |
PetIQ, Inc. | 645.22 Million USD | 69.881% |
Silver Spike Investment Corp. | 3 Million USD | -6356.675% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 80.936% |
Journey Medical Corporation | 56.49 Million USD | -243.962% |
Alimera Sciences, Inc. | 107.35 Million USD | -81.023% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -811.696% |
Assertio Holdings, Inc. | 148.41 Million USD | -30.939% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -10149.925% |
Embecta Corp. | 2.03 Billion USD | 90.456% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2188.844% |
Procaps Group, S.A. | 462.06 Million USD | 57.942% |
PainReform Ltd. | 2.69 Million USD | -7121.665% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -12.082% |
Hempacco Co., Inc. | 18.82 Million USD | -932.466% |
Talphera, Inc. | 6.29 Million USD | -2989.587% |
Pacira BioSciences, Inc. | 704.25 Million USD | 72.406% |
Alvotech | 1.88 Billion USD | 89.677% |
Lantheus Holdings, Inc. | 835.25 Million USD | 76.734% |
Kamada Ltd. | 109.96 Million USD | -76.719% |
Indivior PLC | 1.95 Billion USD | 90.04% |
Currenc Group, Inc. | 177.67 Million USD | -9.376% |
Evoke Pharma, Inc. | 9.64 Million USD | -1914.234% |
Flora Growth Corp. | 17.22 Million USD | -1028.411% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2188.844% |
Evolus, Inc. | 209.68 Million USD | 7.321% |
HUTCHMED (China) Limited | 536.38 Million USD | 63.77% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 77.752% |
Akanda Corp. | 12.66 Million USD | -1433.955% |